InventisBio (SH:688382)2022-10-26 16:00Financial Performance - The net profit attributable to shareholders for the third quarter was -159,755,724.11 RMB, with a year-to-date net profit of -385,003,047.30 RMB[9] - The company reported a net loss of RMB 1,922,264,592.74 for the third quarter of 2022, compared to a net loss of RMB 1,537,261,545.44 in the same quarter of the previous year[32] - The total comprehensive income for the third quarter of 2022 was -386,067,242.25 CNY, compared to -267,534,079.67 CNY in the previous year, reflecting a worsening financial position[42] - The total profit for the third quarter of 2022 was -385,003,047.30 CNY, which is a decline from -266,750,406.12 CNY in the same quarter of 2021[35] - The basic and diluted earnings per share for the third quarter were both -0.30 RMB, with year-to-date figures of -0.79 RMB[11] - The basic and diluted earnings per share for the third quarter of 2022 were both -0.79 CNY, compared to -0.58 CNY in the same quarter of 2021[42] Research and Development - The total R&D investment for the third quarter was 158,219,836.46 RMB, representing a 66.33% increase compared to the same period last year, and a total of 377,257,640.15 RMB year-to-date, which is a 54.88% increase[11] - Research and development expenses for the third quarter of 2022 were RMB 377,257,640.15, an increase from RMB 243,587,590.01 in the same quarter of the previous year, representing a growth of approximately 55%[32] - The company is in the critical registration clinical phase for key products, with steady progress in other clinical and preclinical products[15] Assets and Liabilities - The total assets at the end of the reporting period amounted to 2,468,830,470.68 RMB, reflecting a 208.59% increase compared to the end of the previous year[11] - As of September 30, 2022, the total current assets amounted to RMB 2,410,488,899.48, a significant increase from RMB 741,450,730.79 in the previous year[24] - The total liabilities reached RMB 164,313,012.97, compared to RMB 114,997,432.98 in the same period last year, indicating a growth of approximately 43%[30] - The total equity attributable to shareholders was RMB 2,304,517,457.71, up from RMB 685,029,725.40 year-over-year, reflecting a growth of about 236%[32] - The equity attributable to shareholders at the end of the reporting period was 2,304,517,457.71 RMB, which is a 236.41% increase compared to the end of the previous year[11] Cash Flow - The net cash flow from operating activities year-to-date was -330,711,530.04 RMB[11] - The net cash flow from operating activities for the third quarter of 2022 was -330,711,530.04 CNY, compared to -190,489,709.74 CNY in the previous year, indicating increased cash outflows[44] - The company reported a net cash inflow from operating activities of 16,488,618.50 CNY, down from 19,173,001.91 CNY in the previous year[42] - The cash and cash equivalents as of September 30, 2022, were RMB 2,389,930,861.41, a substantial rise from RMB 724,250,312.28 in the previous year[24] - The cash and cash equivalents at the end of the third quarter of 2022 amounted to 2,389,930,861.41 CNY, up from 802,728,119.40 CNY in the same period of 2021[44] - The company received 1,999,610,000.00 CNY from financing activities in the third quarter of 2022, a significant inflow compared to the previous year[44] - The cash outflow from investing activities in the third quarter of 2022 was 4,386,350.28 CNY, compared to 23,839,895.07 CNY in the same period of 2021, showing a decrease in investment expenditures[43] Government Support and Other Income - The company received government subsidies amounting to 79,113.39 RMB year-to-date, with other operating income and expenses totaling -100,425.66 RMB[12] Other Observations - The company reported no revenue for the third quarter as all products are still in the research and development stage[15] - The company has not disclosed any new product launches or technological advancements in the recent reports[23] - The weighted average return on net assets for the year-to-date was -41.29%[11] - The company reported a credit impairment loss of 11,698.75 CNY in the third quarter of 2022, compared to a loss of -7,832.74 CNY in the previous year[35]